Abstract:9114 Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have a significant therapeutic effect in the treatment of advanced non-small-cell lung cancer (NSCLC). However, patients treated with EGFR-TKIs had a median progression-free survival (PFS) of only 8 to 18 months. The occurrence of acquired resistance greatly limits the survival benefit of TKI for NSCLC patients. Extensive efforts have been paid to find a well-tolerated drug or treatment that works before acquired resistance to EGFR-TKI with low toxicity. Focusing on clinical trials of targeted combination radiotherapy, we observed some encouraging results. Methods: Stage IV NSCLC patients with EGFR sensitive mutation (19DEL or 21L858R) have received first-line EGFR TKIs treatment and achieved stable disease or partial response have been enrolled in this prospective, multicenter, randomized controlled, phaseIIstudy. Recruited from 4 hospitals in China, patients were divided into two groups: Stereotactic Body Radiation Therapy (SBRT) combined with TKIs group as the experimental and TKIs treatment group as an active comparator. The primary endpoint is PFS, and the secondary endpoint aims to overall survival (OS) and safety. To further confirmed these clinical observations in patients, xenograft experiments in nude mice were conducted. To examine the specific mechanism, transcriptome sequencing analysis was performed. Results: Between Mar 2015 and Mar 2018, A total of 61 patients who met the inclusion criteria were randomized to the TKI group and SBRT combined group. The median PFS of the TKI group and SBRT combined group were 9.0 vs 17.6 months (p = 0.016). Meanwhile, the median OS were 23.2 vs 33.6 months (p = 0.026). The total number of patients with T790m was 30(49.1%), and the incidence of T790M did not differ between the two groups. Toxicity data and subgroup analyses including different radiation sites will be presented at the conference. As for the xenograft experiments, data on tumor regression and time of drug resistance of early radiotherapy group was clearly superior to others. Transcriptome sequencing analysis found expression of c-Fos was the key point that led to the phenomena. Conclusions: The addition of SBRT significantly delayed the onset of EGFR TKIs acquired resistance and prolonged the PFS and OS of patients. Radiotherapy for the primary site alone might be superior to metastatic sites. Treatment-related adverse events were generally safe and controllable. The oncogenic role of c-Fos in the effect of radiotherapy on gefitinib resistance and promoting the proliferation of NSCLC cells is confirmed. Clinical trial information: NCT03595644.

Clinical observation on Cyberknife radiosurgery radiotherapy combined with EGFR-TKI in the treatment of 24 patients with advanced non-small cell lung cancer

Clinical outcomes of CyberKnife radiosurgery for patients with peripheral stage Ⅰ non-small cell Lung cancer

Preliminary results for patients with early peripheral non-small cell lung cancer treated by Cyberknife

Clinical Analysis of Cyberknife Stereotactic Surgery for Lung Tumors

Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases.

Clinical analysis of 35 patients with liver tumor treated by cyberknife

Clinical Outcomes of CyberKnife Stereotactic Body Radiotherapy for Peripheral Stage I Non-Small Cell Lung Cancer

Efficacy of stereotactic body radiotherapy in treatment of early-stage peripheral non-small cell lung cancer

Results and prognostic factors of CyberKnife for lung metastasis

Analysis of Clinical Efficacy of CyberKnife(®) Treatment for Locally Advanced Pancreatic Cancer.

Treating Adrenal Tumors In 26 Patients With Cyberknife: A Mono-Institutional Experience

Clinical Observation on the Treatment Efficacy of Cyberknife for Iliac Lymph Node Metastasis

Clinical Observation on the Therapeutic Efficacy of Cyberknife for Primary or Metastastic Retroperitoneal Tumors

Continuing EGFR-TKI in Combination with Super-Selected Arterial Infusion Chemotherapy Beyond RECIST PD for Patients with Advanced EGFR Positive Mutation Non-Small Cell Lung Cancer.

[Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].

Cyberknife Radiosurgery on the Brainstem Metastases of Non-Small Cell Lung Cancer

Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis

EGFR-TKIs with or without Stereotactic Body Radiotherapy to Primary Lesion in the Advanced EGFR-Mutated Non- Small Cell Lung Cancer

Clinical Analysis of Cyberknife Radiosurgery in the Treatment of 26 Patients with Adrenal Gland Neoplasms

EGFR-TKIS Combined with Radioactive 125I Seed Implantation for the Treatment of Advanced Non-Small-cell Lung Cancer：analysis of Clinical Effect

Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.